This provides a potential explanation for drug resistance mechanisms in p53 null colon cancer cells, specifically that loss of p53 leads to lowered degradation of TET2 protein in the cytoplasm, but more accumulation in the nucleus during doxorubicin or cisplatin treatment. The gene discussed is TET2; the disease is colonic neoplasm.